Core Viewpoint - The recent financing move by Merck for sac-TMT indicates a strong commitment to the drug's global development, highlighting its potential in the oncology market [1] Group 1: Company Developments - Kolon Biotech (06990) shares rose over 5%, currently trading at 431.2 HKD with a transaction volume of 106 million HKD [1] - Merck has initiated a rare financing action, securing 700 million USD from Blackstone for the global development of sac-TMT, which is a significant ADC drug licensed to Merck by Kolon Biotech in 2022 [1] Group 2: Strategic Insights - Merck retains decision-making and control rights over the development, production, and commercialization of sac-TMT, exchanging future revenue rights for the financing [1] - The collaboration with Blackstone reflects a deep insight into the potential of sac-TMT, aiming to accelerate its global development process [1] Group 3: Clinical Trials and Market Potential - According to Merck's 2025 ASCO investor communication, nine Phase III clinical trial data releases for sac-TMT are expected between 2027 and 2029, which will further validate its market potential [1] - The upcoming data releases are anticipated to solidify sac-TMT's core position in Merck's global pipeline, serving as a "ballast" in its oncology strategy [1]
科伦博泰生物-B盘中涨超5% 默沙东联手Blackstone加速公司授权产品Sac-TMT全球开发